NCT04794413 is a EARLY_PHASE1 clinical trial of Pimavanserin in Tourette Syndrome, sponsored by Joseph Jankovic.

Who is sponsoring NCT04794413?

NCT04794413 is sponsored by Joseph Jankovic.

What drugs are being tested in NCT04794413?

Interventions in NCT04794413: Pimavanserin.

What condition does NCT04794413 study?

NCT04794413 studies Tourette Syndrome, Tardive Dyskinesia.

Is NCT04794413 still recruiting?

NCT04794413 is currently completed. Last updated 12 March 2021.

Last reviewed 2021-03-12 · How we verify

NCT04794413

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pimavanserin Treatment in TS

Completed EARLY_PHASE1 Last updated 12 March 2021

What this trial tests

EARLY_PHASE1 trial testing Pimavanserin in Tourette Syndrome in 10 participants. Completed in 28 February 2021.

Timeline

12 November 2018

Primary endpoint
28 February 2021

28 February 2021

Quick facts

Lead sponsor	Joseph Jankovic
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	12 November 2018
Primary completion	28 February 2021
Estimated completion	28 February 2021
Sites	1 location across United States

Drugs / interventions tested

Pimavanserin (PIMAVANSERIN) — full drug profile →

Conditions studied

Tourette Syndrome — all drugs for Tourette Syndrome →
Tardive Dyskinesia — all drugs for Tardive Dyskinesia →

Sponsor

Joseph Jankovic

Who can join

18 and older, any sex, with Tourette Syndrome or Tardive Dyskinesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is determining if a drug called Pimavanserin if safe and effective in the treatment of the symptoms of Tourette Syndrome. Pimavanserin is an investigational drug for Tourette Syndrome, which means it has not been approved by the United States Food and Drug Administration (FDA) to treat Tourette Syndrome. Pimavanserin has been approved by the FDA as a treatment for hallucinations in Parkinson's Disease. It is currently marketed under the name NUPLAZID (pimavanserin) capsules by Acadia Pharmaceuticals.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tourette Syndrome Treatment Updates: a Review and Discussion of the Current and Upcoming Literature.
Frey J, Malaty IA. · · 2022 · cited 29× · PMID 35107785 · DOI 10.1007/s11910-022-01177-8
Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome.
Billnitzer A, Jankovic J. · · 2021 · cited 7× · PMID 34307741 · DOI 10.1002/mdc3.13207

Verify or expand the search:

Other trials of Pimavanserin

Trials testing the same drug.

NCT06592833 — Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder · Phase 2 · recruiting
NCT05796167 — Pimavanserin for Sleep in Parkinson Disease · EARLY_PHASE1 · withdrawn
NCT04809116 — Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept · Phase 4 · withdrawn
NCT05555615 — Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder · Phase 2, PHASE3 · terminated
NCT04373317 — Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis · Phase 4 · recruiting

Other recruiting trials for Tourette Syndrome

Currently open trials in the same condition.

NCT07203469 — Where Wild Things Grow: Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth · NA · recruiting
NCT06679790 — Trajectories of Change in Tourette Syndrome · NA · recruiting
NCT06678737 — CBIT+TMS R33 Phase · Phase 2 · recruiting
NCT06909656 — Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome · NA · recruiting
NCT06785532 — Effect of RNS in Treatment-refractory Tourette's Syndrome · NA · recruiting

Other Joseph Jankovic trials

Trials by the same sponsor.

NCT00642057 — Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04794413 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Joseph Jankovic
Last refreshed: 12 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04794413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing